Overall, the increased galunisertib concentration at the target site provided by the enteric matrix, and the L1‐CAM inhibition by the active‐targeted NPs could lead to enhanced therapeutic outcomes for CRC treatment. Here, L1CAM is linked to colorectal carcinoma.